Method and system for implementing consistency groups with virtual machines

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Nutanix, Inc. patent solves the following problem:

There are many types of architectures that can be used in storage systems. Traditionally, storage in a computing system implemented using the directly attached or integrated storage, such as hard disk drive, which is often integrated into the personal computer. Distributed storage architectures also widely used, allowing a computer to access and store data on networked based storage devices.

Our analysis of this patent is as follows:

Nutanix, Inc.’s patent US 9069708 B2 deals with Method and system for implementing consistency groups with virtual machines.
Disclosed is a method for the implementation of disaster recovery for virtual machines. Consistency groups are implemented for the virtual machine, where the consistency group link two or more VMs. The consistency group includes any set of VMs that should be handled on a consistent basis in the event of a disaster recovery scenario.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The The United States Of America As Represented By The Secretary, Department Of Health And Human Services, , The Rockefeller University, , Icahn School Of Medicine At Mount Sinai patent solves the following problem:

Platelet accumulation in the area of ​​vascular injury is a dynamic process that mediates formation of the primary hemostatic plug and pathologic thrombus formation. The mechanism of platelet surface proteins directly platelet thrombi recruitment under flow conditions studied in detail. In addition to managing the initial platelet adhesion, interactions cell-surface receptor activated intracellular signaling. Intracellular signaling stimulates the release of thrombogenic things from platelet granules. Signaling also mediates activation of the platelet integrin IIB3 facilitating strong adhesion of platelets to the site of injury.

Our analysis of this patent is as follows:

The United States Of America As Represented By The Secretary, Department Of Health And Human Services, , The Rockefeller University, , Icahn School Of Medicine At Mount Sinai’s patent US 9066948 B2 deals with Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines.
The present invention relates to compounds of formula P-1 and related compounds and compositions useful for inhibiting and / or reducing platelet deposition, extrusion and / or aggregation. The definition of a, Y, R1, R2, Ra, Ra, RB, RB, RC, RC, Rd, Rd, Re, and Pin is given here. The present invention further relates to methods for treating or Branch Tomato thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, sudden closure following angioplasty or stent placement, and thrombosis as a result of vascular surgery.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Engeneic Molecular Delivery Pty Ltd. patent solves the following problem:

Recently, a number of nucleic acid-based methods have also developed a variety of cellular functions (Opalinska and Gewirtz, 2002). Classes of oligonucleotides such as aptamers, transcription factor binding decoy oligonucleotides, ribozymes, triplex-forming oligonucleotides, immunostimulatory CPG motive, antisense oligonucleotides (including peptide nucleic acid), small interfering RNAs, microRNAs taken much interest as research tools, because in some very specific ways of action. These oligomeric nucleic acid that has considerable potential as therapeutics, too. Such therapeutics face several obstacles, however, including the instability of the free nucleic acid and the safe, orderly and targeted cellular delivery of these macromolecules (Dykxhoorn and Lieberman, 2005).

Our analysis of this patent is as follows:

Engeneic Molecular Delivery Pty Ltd.’s patent US 9066982 B2 deals with Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells.
First, bacterially-derived minicells can safely introduce therapeutically effective amount of plasmid-free functional nucleic acid target mammalian cells. To this end, functional nucleic acid can be packaged into the minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Prophylactic or ameliorating agent for pigmentation

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Pola Chemical Industries Inc. patent solves the following problem:

For example, the pigmentation, freckle, melasma, and senile lentigo, which causes the skin after suntan, living in such a state that the melanin production was held for the activation of pigment cells (melanocytes ) skin. The component, known as the function of preventing or ameliorating the onset and deterioration of the skin pigment disorder as described above, the compound (skin whitening agent) with skin whitening function including, for ex- example, ascorbic acid derivatives, hydrogen peroxide, colloidal sulfur, glutathione, hydroquinone, and catechol (see, for example, Non-Patent Document 1 and Non-Patent Document 2). Besides preparations for the skin, which is blended with components as described above as the active ingredient, are widely used. Today, a variety of mechanisms of action to report as to the mechanism of action belonging to the compound known as the skin whitening agents, including, for example, the tyrosinase enzyme inhibiting action, tyrosinase-related protein in shame, and the melanin transfer ban for the suppression of dendrite elongation in melanocyte. Target molecules are with respect to the respective mechanisms of action. To declare the high skin whitening effect, an organic low molecular weight compound, which appropriately interact with target molecules, useful. Furthermore, the organic low molecular weight compound, which appropriately interact with each of the target molecule, has structural characteristics that differ depending on each of the target molecule. Therefore, the study did so strongly in relation to the optimization of the chemical structure to maximally make use of the medical action showed the organic low molecular weight compound. Today, the study of skin whitening agents is not limited to compound with high efficiency and high selectivity with respect to the current target molecules, study and expanded, for example, the compound act together in a plural skin whitening target molecule and the compound has a novel mechanism of action. The high skin whitening action expected for skin whitening agents as described above. In fact, the screening is carried out in relation to the compounds have excellent skin whitening functions while seeking for useful compounds of various chemical structures or medicinal qualities. Any skin whitening agent, has a novel scaffold, said until now.

Our analysis of this patent is as follows:

Pola Chemical Industries Inc.’s patent US 9066914 B2 deals with Prophylactic or ameliorating agent for pigmentation.
One thing the present invention is to provide a prophylactic or ameliorating agent for natural color with a novel pulpit and an external preparation for skin containing the same as a component. something achieved by providing a prophylactic or ameliorating agent for natural color contains a compound represented by the following general formula (1), an isomer thereof, and / or a pharmacologically acceptable salt thereof, and an external preparation for skin containing the same as a component: [wherein R1 represents a hydrogen atom or a linear or branched chain alkyl group 1 to 8 carbon (s) atoms; R2 represents a hydrogen atom, a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 8 carbon (s) atoms, a substituted or unsubstituted aromatic group, a substituted or unsubstituted polycyclic fused aromatic groups, or a substituted or unsubstituted heterocyclic group having a 5 to 12 carbon atoms; P3 represents a substituted or unsubstituted aromatic group, a substituted or unsubstituted polycyclic fused aromatic group, or a substituted or unsubstituted heterocyclic group having a 5 to 15 carbon atoms; n represents an integer of 1 or 2; and m represents an integer of 0 to 3.]

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Semiconductor chip with modified regions for dividing the chip

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Renesas Electronics Corporation patent solves the following problem:

In recent years, with reduced size and weight of the mobile device as described in cellular phones and digital cameras, and store information media as described in memory cards, semiconductor chips embedded these made thinner. Therefore, while a dicing process have individual thin semiconductor chips by cutting a thin semiconductor wafer, chip tends to occur in semiconductor chips because of their thinness in a dicing process use a blade dicing methods, thus causing a problem in the significant decrease in the bending strength of thin semiconductor chips. Furthermore, although a low-dielectric-constant film (called Low-k film) having a dielectric constant lower than silicon oxide is used for an insulating film between wiring layers layers of a semiconductor chip in view of developing an operation speed of a semiconductor device, as a Low-k film is brittle and tends to bark, and have subtle air bubbles in it, and therefore can not be cut by the blade dicing.

Our analysis of this patent is as follows:

Renesas Electronics Corporation’s patent US 9070560 B2 deals with Semiconductor chip with modified regions for dividing the chip.
A semiconductor wafer with a modified region formed on the substrate is provided. A modified region formed outside the side of a wafer, and a pad that is formed on an insulating film, which formed on the first surface of the substrate wafers . Furthermore, the modified region formed closer to the side surface of the substrate with the pad. In this way, cutting defects in the form of a cutting process on a semiconductor wafer using secret dicing can be reduced or prevented.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Therapeutic method for mesothelioma

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The National University Corporation Kanazawa University, , Kyowa Hakko Kirin Co., Ltd. patent solves the following problem:

The present invention relates to a therapeutic method and a diagnostic method using the antibody that binds to ganglioside GM2 antigen. The invention also relates to a therapeutic agent and a diagnostic agent that contains antibodies that bind to ganglioside GM2 antigen as active ingredients.

Our analysis of this patent is as follows:

National University Corporation Kanazawa University, , Kyowa Hakko Kirin Co., Ltd.’s patent US 9066929 B2 deals with Therapeutic method for mesothelioma.
The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent that contains as a active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved through the diagnosis and treatment of GM2 positive mesothelioma patient with a diagnostic agent and a therapeutic agent consisting of an anti-ganglioside GM2 antibody as an active ingredient.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Ion mobility separator with variable effective length

File for Quick & Easy Patent Protection with PowerPatent.

The Micromass Uk Limited patent solves the following problem:

The present invention relates to the field of mass spectrometry and in particular ion mobility spectrometry.

Our analysis of this patent is as follows:

Micromass Uk Limited’s patent US 9070543 B2 deals with Ion mobility separator with variable effective length.
An ion mobility separator or spectrometer revealed that consists of an inner cylinder and an outer cylinder defining an annular volume through which ion transmitted. Spiral electrodes af arranged on a surface of the inner cylinder and / or a face of the outer cylinder. A first device arranged and adapted to maintain a DC electric field and / or a mini-potential force working to encourage ion from a first end of the ion mobility separator or spectrometer to a second end of the ion mobility separator or spectrometer. The second device arranged and adapted for use in transient DC voltages on one or more spiral electrodes to encourage ion to the first end of the ion mobility separator or spectrometer. The net effect is to extend the effective path length of the ion mobility separator.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Interference control

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Nokia Solutions And Networks Oy patent solves the following problem:

Our analysis of this patent is as follows:

Nokia Solutions And Networks Oy’s patent US 9072059 B2 deals with Interference control.
When it is determined that a first estimate of the general level of interference to transmissions associated with a first access node from the transmissions associated with other nodes access more predetermined target maximum rate; then confidence in the area said the first estimate exceeds said target maximum value, select one or more of said other access nodes to make a request to reduce the transmission power of interfering transmissions, and / or selecting a price to ask of any one or more of said other access node to reduce the transmission power of interfering transmissions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

C-Met receptor regulation by angiotensin IV (AT4) receptor ligands

File for Quick & Easy Patent Protection with PowerPatent.

The Washington State University patent solves the following problem:

Embodiments of the invention disclosed here relates generally to compositions and methods for the hepatocyte growth factor activity or c-Met receptor activity. Some aspects related to the diagnosis, prevention or treatment, as well as general therapy in subjects with, suspected of, or susceptible to, a condition related to the c-Met receptor dysregulation. P-Met receptor dysregulation may be a situation underactivity, overactivity or improper activity in a Met cellular or molecular event is today, including obesity or a condition associated with obesity, a hyperproliferative disorder, a condition characterized by abnormal angiogenesis, or on the other hand, a condition characterized by vascular shortage as possible to benefit more angiogenesis. Embodiments disclosed in further relates to methods for recognition or modification of compounds useful for the diagnosis, prevention or treatment of such conditions associated with c-Met receptor dysregulation.

Our analysis of this patent is as follows:

Washington State University’s patent US 9066901 B2 deals with C-Met receptor regulation by angiotensin IV (AT4) receptor ligands.
Angiotensin-like composition of matter and methods of using them in the diagnosis, prevention and / or treatment of conditions associated with c-Met dysregulation given. The conditions include cancer, obesity, conditions associated with obesity, and neurodegenerative diseases such as general dementia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury and spinal cord trauma.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Personalized electronic-mail delivery

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Dell Software Inc. patent solves the following problem:

The present invention relates generally to a method and system for making a personal display for a user of an electronic network. More particularly, the present invention relates to a method and system for determining the interests of a user from within the electronic documents viewed by the user and provide recommended documents and recommendations packages in a user based on the determined interest.

Our analysis of this patent is as follows:

Dell Software Inc.’s patent US 9069845 B2 deals with Personalized electronic-mail delivery.
Personalized electronic mail delivery revealed. The contents of incoming messages to electronic mail known. Determining be made with respect to whether in future electronic messages-mail equivalent of a user profile. The user profile may indicate one or more users in a particular user with respect to future messages from electronic mail. If the incoming messages to electronic-mail correspond to one or more user profile shows the user, the electronic-mail messages to be saved in an electronic-mail server. The electronic-mail messages can be shown to the user with a list of messages in the electronic-mail messages reflective stored in the electronic-mail server and accessible to the end-user.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.